Among its findings, the report notes:
1. The global market for gastrointestinal drugs reached $35.7 billion in 2015.
2. The market is expected to reach $48.4 billion by 2022, growing at a CAGR of 4.45 percent.
3. At present, AbbVie is leading the market; however, Takeda Pharmaceutical is expected to be the leading market player by the end of 2022.
4. Other key market players include Johnson & Johnson, Allergan and AstraZeneca.
5. GBI Research says that this increase in market value is, in part, due to a growing interest in biologic products.
More articles on gastroenterology and endoscopy:
Cologuard included in 2017 HEDIS quality measures for CRC screening: 4 notes
Allergan buys rights to AstraZeneca’s IBD treatment drug for $250M: 3 notes
Global market for endoscopic devices to grow at 7.06% CAGR until 2020: 5 notes
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.